inVentiv: 'site-centricity' essential to enhance trial conduct
SCRS announced that inVentiv has become a Site Engagement Partner, and as such will continue to participate on the SCRS Global Impact Board, which works with the association’s leadership council to provide advice on strategic initiatives for SCRS.
Additionally, inVentiv will host two Site Advocacy Groups (SAGs) in order to gain insights from other SCRS members.
"inVentiv’s expanded partnership with SCRS indicates an awareness of the essential role of sites in clinical research operations,” Christine Pierre, President, SCRS, told Outsourcing-Pharma.com.
“Site Advocacy Groups (SAGs) bring the site voice directly into process development and highlight obstacles that could have held up essential advances," she added.
Susan Stansfield, PhD, Executive Vice President, Site Centricity Unit, Clinical Division, inVentiv Health, told us the company believes “elevating the ‘voice’ of clinical sites holds tremendous potential for improving clinical trial execution.”
The company calls this approach “site-centricity,” which Stansfield says is essential for enhancing trial conduct in an important stage – “during the study start-up period culminating with site activation.”
As part of this approach the company works with sites to develop solutions to challenges in order to improve delivery of medicines to the market.
Through its position on the SCRS Global Impact Board, inVentiv Health is currently working with SCRS to provide counsel on Site Performance Dashboard and Site Payment approaches.
“Working side-by-side with SCRS membership of dedicated SAGs, we’ll be tackling areas where we believe we can jointly add-value to improving site performance and satisfaction in clinical research,” said Stansfield.
“We believe that through these forums we can uncover actionable insights that will translate into long-term improvements for inVentiv clients and the industry.”